New Delhi, Oct 24 (UNI) Oncology drug maker Dabur Pharma Ltd today said it has entered into a supply and distribution agreement with one of Spain's leading generic firm Combino Pharm to distribute and market generic oncology products in the 750 million dollar Spanish market.
The Spanish generic market is currently one of the fastest growing in the world with an annual growth rate of 25 per cent.
Dabur Pharma will be responsible for registration and supply of products, while Combino Pharm will handle the distribution, marketing and sales aspects, a statement said.
''Both companies expect to benefit significantly from each other's strengths and the partnership should enable both to establish a significant presence in the Spanish oncology market,'' company's CEO Ajay Kumar Vij said.
The company, which already has approvals for three products in the United Kingdom, said it expects to begin shipping the products to the Spanish market shortly and is awaiting Mutual Recognition Procedure (MRP) approval for its products from the Spanish Regulatory Authority.